Johnson & Johnson
JNJ is executing well operationally, but at $271.22 the stock already discounts most of the FY26 recovery while the quant base value is $263.08, STELARA erosion is severe at -55.7%, and the shares sit just 3.5% below the 52-week and 5-year high.
JNJ is a good company and a weak stock at this price. The business is proving more resilient than many expected into the STELARA cliff, but the market already knows that. At $271.22, with the shares just 3.5% below the 52-week high and 12.9% above the 200-day average, the setup looks late rather than early. The quant engine's fair value is $263.08, and even that assumes enough earnings durability to keep the blended outcome from collapsing toward the much lower $168.4 P/S valuation.
The core issue is not execution. Management is executing. FY26 guidance was raised to $100.6B operational sales at the midpoint and $11.50-$11.65 adjusted operational EPS, after a Q2 beat and a $400M guide increase. Innovative Medicine grew 6.8% operationally, TREMFYA surged 71%, and the company said growth excluding STELARA was double digit. That is exactly what competent operators should deliver when a major product loses exclusivity.
The problem is what investors are paying for that competence. The stock trades at 31.29x trailing earnings and 6.74x sales, a premium to the peer P/S of 4.3, despite a growth profile that is still mid single digit and a margin profile under pressure. Q2 EBITDA margin was 28.3%, down 850 bps year over year, and adjusted enterprise pre-tax margin slipped 30 bps on launch spend and tariffs. STELARA was down 55.7%, so the company has to keep replacing a large earnings stream while spending heavily on launches, manufacturing, and pipeline.
The short case depends on three things. First, the stock rerates modestly toward fair value as the market stops paying peak-defensive multiples for a business with visible LOE. Second, STELARA erosion remains a real drag even if the rest of the portfolio performs well. Third, MedTech stays decent but not strong enough to provide a second engine, especially with cardiovascular growth at only 3.1% and China still uneven. What would change the view is a cleaner proof that FY27 can grow from the new base without further margin slippage, ideally with sustained double-digit ex-STELARA portfolio growth translating into visibly stronger free cash flow.
TREMFYA, RYBREVANT, and other launches drive cleaner 2027 growth, margins stabilize, and investors keep paying a premium defensive multiple.
Management hits the raised FY26 guide, launches offset much of the LOE pressure, but valuation drifts toward the engine's blended fair value.
STELARA erosion stays worse than expected, MedTech remains sluggish, and the market rerates JNJ closer to a lower-growth defensive multiple.
Quant call (HOLD) diverges from analyst consensus (Strong Buy: 10 buy / 1 hold / 0 sell) — resolve explicitly.
We suffer more often in imagination than in reality.
Forward earnings power looks solid, but not cheap enough to chase here. Against FY26 adjusted operational EPS guidance of $11.50-$11.65, the stock trades at roughly 23x-24x forward earnings, which is more reasonable than the trailing 31.29x but still rich for a company growing sales around 7% with visible LOE and margin pressure. The moat remains strong over the next 3 to 5 years because Innovative Medicine and MedTech still have scale, regulatory know-how, and global distribution, but it is not widening as biosimilars attack mature assets and MedTech growth stays uneven. AI is a support tool rather than a thesis changer for JNJ, helpful in discovery, manufacturing, and trial efficiency, but unlikely to create the kind of step-change that would justify a premium multiple expanding from here. Regulation remains a real drag because pharma pricing and biosimilar substitution matter more to this story than any AI upside.
- Quant target is $263.08, implying -3.0% from $271.22, with valuation methods split between high multiple outcomes near $301.6-$301.68 and a much lower P/S value of $168.4.
- FY26 guidance was raised to $100.6B operational sales midpoint and $11.50-$11.65 adjusted operational EPS, but the stock already sits 12.9% above its 200-day average and only 3.5% below its all-time high.
- Core execution is solid, but STELARA fell 55.7%, Q2 EBITDA margin dropped to 28.3% from 36.8% a year earlier, and adjusted enterprise pre-tax margin was down 30 bps year over year.
- Management raised FY26 guidance after Q2, now calling for 6.5%-7.1% operational sales growth and $11.50-$11.65 adjusted operational EPS, with the sales outlook lifted by $400M.
- Innovative Medicine remains healthy at +6.8% operational growth, and excluding STELARA the company said overall growth was double digits, showing the portfolio is not rolling over with the LOE.
- Newer products are gaining real traction, especially TREMFYA +71%, while launches including ICOTYDE, INLEXZO, and RYBREVANT are supporting a stronger second half.
- Execution has been dependable, with 8 straight quarters at or above EPS expectations, including beats of +9.5%, +7.4%, and +3.4% over the last two years.
- Valuation leaves little room for error, at 31.29x earnings and 6.74x sales versus a peer average P/S of 4.3, while the engine's target is still below spot at $263.08.
- STELARA erosion is now a hard earnings headwind, with sales down 55.7% from biosimilar competition, and that hole has to be filled by launches that still require investment.
- Profit conversion looks weaker than the headline growth story, with FY2025 EPS down 58.6% year over year to $11.03, FY2025 FCF only $3.4B, and Q2 FY26 EBITDA margin compressed to 28.3%.
- MedTech is not firing on all cylinders, with cardiovascular growth slowing to 3.1% because of Abiomed softness and China EP inventory pressure, which limits diversification against pharma LOE.
| Metric | Value | Context |
|---|---|---|
| Current price | $271.22 | Reference price for this note |
| Quant price target | $263.08 | -3.0% vs current, Medium confidence, basis earnings_growth_blend |
| FY2025 revenue | $94.2B | +3.7% YoY |
| FY2025 EPS | $11.03 | -58.6% YoY |
| Operating margin | 24.8% | vs 24.9% prior FY |
| Valuation | P/E 31.29, P/S 6.74, P/B 7.77 | Peer avg P/E 34.6, peer avg P/S 4.3 |
| Balance sheet leverage | Debt/Equity 0.58, Debt/EBITDA 1.19 | Moderate leverage for a mega-cap healthcare platform |
| FY2025 free cash flow | $3.4B | Well below FY26 management expectation of about $21B |
| FY26 guidance | $100.6B sales midpoint, $11.50-$11.65 adj. operational EPS | Operational sales growth 6.5%-7.1%, reported sales midpoint $101.1B |
| Q2 FY26 profitability | EBITDA $7.17B, margin 28.3% | Down 610 bps vs Q1 and 850 bps vs Q2'25 |
| Price action / 52-week position | -3.5% vs 52-week high, +12.9% vs 200-day | Stock is near its high, not washed out |
The main risk to a SELL call is that JNJ delivers enough launch-driven acceleration to sustain FY26 EPS at $11.50-$11.65 and carry that momentum into 2027, forcing investors to keep paying above 31x earnings for a defensive compounder.
The next catalyst is Q3 earnings on October 13, 2026, where the key test is whether second-half acceleration and launch uptake are strong enough to offset the 55.7% STELARA decline and defend the raised FY26 guide.
Ownership is crowded and stable, with the top 3 institutions holding 69.4%, insiders at 0.0%, and short interest only 0.88% of shares, or 21.2M shares and 2.8 days to cover. That usually means little squeeze fuel and limited forced buying from shorts. Options positioning is mildly supportive near term because the gamma regime is positive and zero-gamma sits at $260.07, but that is a trading cushion, not a fundamental valuation argument.
Q2 FY26 operational growth was +6.8%, with strength in new launches and TREMFYA +71%, partly offset by STELARA -55.7%.
Growth is positive but less consistent, with softer cardiovascular trends and 3.1% growth in that business because of Abiomed softness and China EP inventory headwinds.
JNJ is committing >$1B to expand U.S. Vision manufacturing, packaging, and distribution, signaling confidence in domestic demand and supply chain localization.
China remains a swing factor for MedTech, with management previously guiding no material improvement there through 2024 and inventory pressure still showing up in FY26.
JNJ posted a Q2 beat and raised FY26 guidance on stronger Innovative Medicine momentum.
Management has earned credibility on near-term delivery. In the 2024 Q3 call, JNJ raised FY2024 operational sales guidance to $89.4B-$89.8B and adjusted operational EPS to $9.87-$9.95, while saying it could "consistently beat financial expectations." Since then, the company has posted 8 straight quarters at or above EPS expectations, with beats ranging from +0.7% to +9.5%, and in 2026 Q2 it again beat and raised FY26 guidance to $100.6B operational sales midpoint and $11.50-$11.65 adjusted operational EPS. The 2024 concern around STELARA proved real, with sales now down 55.7%, but management also said in 2024 that Innovative Medicine could grow despite LOE, and current +6.8% Innovative Medicine growth, plus TREMFYA +71% and stronger launch uptake, supports that claim. Direction has not changed materially: the company is still leaning on Innovative Medicine launches, CARVYKTI and RYBREVANT scale-up, and selective platform M&A like Firefly Bio while preparing the Orthopedics separation for mid-2027.
We said 2026 would be a year of accelerated growth and impact for Johnson & Johnson, and with our Q2 beat on the top and bottom line and raised guidance, we are delivering.
Driven by second quarter performance and uptake of new product launches, we are increasing operational sales growth by $400 million, now expecting operational sales growth for the full year to be in the range of 6.5%-7.1%, with a midpoint of $100.6 billion.
We are pleased to increase our adjusted operational earnings per share range to $11.50-$11.65, which equates to an increase of $0.18 at the midpoint.
As we look at the remainder of the year, based on year-to-date performance and updated guidance, we anticipate operational sales growth to improve in the second half of the year.
We see the second half of the year as stronger. That momentum is carried into 2027, and we continue to see double-digit growth by the end of the decade.
JNJ's moat is built on scale across pharma and MedTech, deep regulatory experience, a global commercial footprint, and a product engine that can fund launches even through major patent losses. That moat is still durable, but it is not invulnerable: STELARA -55.7% shows how quickly a large franchise can reset once biosimilars hit. The moat looks intact, not strengthening, because replacement products are working but require continued spending and execution.
Capital allocation looks conservative, but not especially accretive at this valuation. In the latest deep-dive data, JNJ generated $3.4B of free cash flow, spent $3.2B on dividends, only $0.2B on buybacks, and $1.3B on capex, while management also plans >$1B of U.S. Vision capacity investment. That mix favors durability and income over aggressive repurchases, which is sensible for a mature healthcare leader, though it limits per-share upside if growth stays mid single digit.
Rated SELL, Medium conviction. JNJ is executing through a difficult product transition, but the stock already prices in that competence and offers a worse entry point than the fundamentals justify. The key distinction is business quality versus stock price: business quality is solid, stock price is too full. A move closer to the $263.08 base value, or clear evidence that FY27 earnings and free cash flow can accelerate without additional margin damage, would soften the stance. Until then, this is a trim, not a chase.
≣ Full research note tap to expand
Executive Summary
SELL, Medium conviction. Rated SELL, Medium conviction. JNJ is not a broken business, but it is an expensive defensive stock with modest upside to fundamentals and a clear valuation disconnect versus the engine's $263.08 target, or -3.0% from the current price. Management has executed through the STELARA loss of exclusivity, yet the stock trades at 31.29x earnings and 6.74x sales while free cash flow was only $3.4B in FY2025 and margin pressure remains visible in FY26.
Investment Thesis
JNJ is a good company and a weak stock at this price. The business is proving more resilient than many expected into the STELARA cliff, but the market already knows that. At $271.22, with the shares just 3.5% below the 52-week high and 12.9% above the 200-day average, the setup looks late rather than early. The quant engine's fair value is $263.08, and even that assumes enough earnings durability to keep the blended outcome from collapsing toward the much lower $168.4 P/S valuation.
The core issue is not execution. Management is executing. FY26 guidance was raised to $100.6B operational sales at the midpoint and $11.50-$11.65 adjusted operational EPS, after a Q2 beat and a $400M guide increase. Innovative Medicine grew 6.8% operationally, TREMFYA surged 71%, and the company said growth excluding STELARA was double digit. That is exactly what competent operators should deliver when a major product loses exclusivity.
The problem is what investors are paying for that competence. The stock trades at 31.29x trailing earnings and 6.74x sales, a premium to the peer P/S of 4.3, despite a growth profile that is still mid single digit and a margin profile under pressure. Q2 EBITDA margin was 28.3%, down 850 bps year over year, and adjusted enterprise pre-tax margin slipped 30 bps on launch spend and tariffs. STELARA was down 55.7%, so the company has to keep replacing a large earnings stream while spending heavily on launches, manufacturing, and pipeline.
The short case depends on three things. First, the stock rerates modestly toward fair value as the market stops paying peak-defensive multiples for a business with visible LOE. Second, STELARA erosion remains a real drag even if the rest of the portfolio performs well. Third, MedTech stays decent but not strong enough to provide a second engine, especially with cardiovascular growth at only 3.1% and China still uneven. What would change the view is a cleaner proof that FY27 can grow from the new base without further margin slippage, ideally with sustained double-digit ex-STELARA portfolio growth translating into visibly stronger free cash flow.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Current price | $271.22 | Reference price for this note |
| Quant price target | $263.08 | -3.0% vs current, Medium confidence, basis earnings_growth_blend |
| FY2025 revenue | $94.2B | +3.7% YoY |
| FY2025 EPS | $11.03 | -58.6% YoY |
| Operating margin | 24.8% | vs 24.9% prior FY |
| Valuation | P/E 31.29, P/S 6.74, P/B 7.77 | Peer avg P/E 34.6, peer avg P/S 4.3 |
| Balance sheet leverage | Debt/Equity 0.58, Debt/EBITDA 1.19 | Moderate leverage for a mega-cap healthcare platform |
| FY2025 free cash flow | $3.4B | Well below FY26 management expectation of about $21B |
| FY26 guidance | $100.6B sales midpoint, $11.50-$11.65 adj. operational EPS | Operational sales growth 6.5%-7.1%, reported sales midpoint $101.1B |
| Q2 FY26 profitability | EBITDA $7.17B, margin 28.3% | Down 610 bps vs Q1 and 850 bps vs Q2'25 |
| Price action / 52-week position | -3.5% vs 52-week high, +12.9% vs 200-day | Stock is near its high, not washed out |
Financial Strength
JNJ still has a sound balance sheet for its size, with Debt/EBITDA of 1.19 and Debt/Equity of 0.58, so solvency is not the issue. The more important read is that cash generation and margins have not looked as clean as the valuation implies: FY2025 free cash flow was only $3.4B, current ratio is 1.09, and Q2 FY26 EBITDA margin fell to 28.3% from 36.8% a year earlier. This is financially sturdy, but not the kind of balance-sheet and cash-flow profile that obviously deserves a premium defensive multiple at a record-ish stock price.
Competitive Position
JNJ's moat is built on scale across pharma and MedTech, deep regulatory experience, a global commercial footprint, and a product engine that can fund launches even through major patent losses. That moat is still durable, but it is not invulnerable: STELARA -55.7% shows how quickly a large franchise can reset once biosimilars hit. The moat looks intact, not strengthening, because replacement products are working but require continued spending and execution.
Management & Guidance
Management's current FY26 guide is constructive and, on balance, credible. After the Q2 beat, JNJ lifted operational sales growth to 6.5%-7.1%, or $100.6B at the midpoint, and raised adjusted operational EPS to $11.50-$11.65, while keeping free cash flow on track for about $21B. The credibility comes from the company's recent beat record and the fact that the raised guide is tied to identified launch momentum, especially TREMFYA, RYBREVANT, ICOTYDE, and INLEXZO, rather than vague optimism. The check on that credibility is margin pressure, because management is funding launches, capacity, and platform M&A while absorbing STELARA erosion.
Segment Analysis
- Innovative Medicine (N/A): Q2 FY26 operational growth was +6.8%, with strength in new launches and TREMFYA +71%, partly offset by STELARA -55.7%.
- MedTech (N/A): Growth is positive but less consistent, with softer cardiovascular trends and 3.1% growth in that business because of Abiomed softness and China EP inventory headwinds.
- United States (N/A): JNJ is committing >$1B to expand U.S. Vision manufacturing, packaging, and distribution, signaling confidence in domestic demand and supply chain localization.
- International (N/A): China remains a swing factor for MedTech, with management previously guiding no material improvement there through 2024 and inventory pressure still showing up in FY26.
Capital Allocation
Capital allocation looks conservative, but not especially accretive at this valuation. In the latest deep-dive data, JNJ generated $3.4B of free cash flow, spent $3.2B on dividends, only $0.2B on buybacks, and $1.3B on capex, while management also plans >$1B of U.S. Vision capacity investment. That mix favors durability and income over aggressive repurchases, which is sensible for a mature healthcare leader, though it limits per-share upside if growth stays mid single digit.
Management Execution & Track Record
Management has earned credibility on near-term delivery. In the 2024 Q3 call, JNJ raised FY2024 operational sales guidance to $89.4B-$89.8B and adjusted operational EPS to $9.87-$9.95, while saying it could "consistently beat financial expectations." Since then, the company has posted 8 straight quarters at or above EPS expectations, with beats ranging from +0.7% to +9.5%, and in 2026 Q2 it again beat and raised FY26 guidance to $100.6B operational sales midpoint and $11.50-$11.65 adjusted operational EPS. The 2024 concern around STELARA proved real, with sales now down 55.7%, but management also said in 2024 that Innovative Medicine could grow despite LOE, and current +6.8% Innovative Medicine growth, plus TREMFYA +71% and stronger launch uptake, supports that claim. Direction has not changed materially: the company is still leaning on Innovative Medicine launches, CARVYKTI and RYBREVANT scale-up, and selective platform M&A like Firefly Bio while preparing the Orthopedics separation for mid-2027.
Positioning & Flows
Ownership is crowded and stable, with the top 3 institutions holding 69.4%, insiders at 0.0%, and short interest only 0.88% of shares, or 21.2M shares and 2.8 days to cover. That usually means little squeeze fuel and limited forced buying from shorts. Options positioning is mildly supportive near term because the gamma regime is positive and zero-gamma sits at $260.07, but that is a trading cushion, not a fundamental valuation argument.
Bull Case
- Management raised FY26 guidance after Q2, now calling for 6.5%-7.1% operational sales growth and $11.50-$11.65 adjusted operational EPS, with the sales outlook lifted by $400M.
- Innovative Medicine remains healthy at +6.8% operational growth, and excluding STELARA the company said overall growth was double digits, showing the portfolio is not rolling over with the LOE.
- Newer products are gaining real traction, especially TREMFYA +71%, while launches including ICOTYDE, INLEXZO, and RYBREVANT are supporting a stronger second half.
- Execution has been dependable, with 8 straight quarters at or above EPS expectations, including beats of +9.5%, +7.4%, and +3.4% over the last two years.
Bear Case
- Valuation leaves little room for error, at 31.29x earnings and 6.74x sales versus a peer average P/S of 4.3, while the engine's target is still below spot at $263.08.
- STELARA erosion is now a hard earnings headwind, with sales down 55.7% from biosimilar competition, and that hole has to be filled by launches that still require investment.
- Profit conversion looks weaker than the headline growth story, with FY2025 EPS down 58.6% year over year to $11.03, FY2025 FCF only $3.4B, and Q2 FY26 EBITDA margin compressed to 28.3%.
- MedTech is not firing on all cylinders, with cardiovascular growth slowing to 3.1% because of Abiomed softness and China EP inventory pressure, which limits diversification against pharma LOE.
Valuation & Price Target
Engine price target $263.08 (-3% vs current), Medium confidence.
- P/E Multiple: $301.68 (28% weight)
- P/S Multiple: $168.4 (20% weight)
- Quality-adjusted: $301.6 (20% weight)
- DCF: $266.02 (14% weight)
The quant baseline is HOLD with a $263.08 target, and this note leans more negative with a SELL because the stock is priced above fair value while sitting near its high, not because the business is deteriorating. The case for a downgrade from HOLD is simple: current price is $271.22, target is -3.0% lower, the shares are only 3.5% below the high, and valuation still looks full at 31.29x trailing earnings and 6.74x sales. The wide peer P/E dispersion of 7.8x also matters because the higher multiple methods, $301.68 P/E and $301.6 quality-adjusted, lean on comparables that are not especially clean for a diversified healthcare company facing a major LOE. Sell-side consensus is Strong Buy, 10 buy / 1 hold / 0 sell, but that is low-signal here and does not change the basic point that execution is already reflected in the price.
Risk Assessment
Risk score 51/100 (Moderate). The main risk to a SELL call is that JNJ delivers enough launch-driven acceleration to sustain FY26 EPS at $11.50-$11.65 and carry that momentum into 2027, forcing investors to keep paying above 31x earnings for a defensive compounder.
The Bottom Line
Rated SELL, Medium conviction. JNJ is executing through a difficult product transition, but the stock already prices in that competence and offers a worse entry point than the fundamentals justify. The key distinction is business quality versus stock price: business quality is solid, stock price is too full. A move closer to the $263.08 base value, or clear evidence that FY27 earnings and free cash flow can accelerate without additional margin damage, would soften the stance. Until then, this is a trim, not a chase.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr